Latigo Biotherapeutics

Uniquely poised to disrupt pain therapy

Thousand Oaks, United States · Founded 2018 · $285.0M raised

Founded
2018
Business Model
B2B
Total Funding
$285.0M
Last Round
$150.0M Series BMar 2025
Rounds
2

About

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines that target pain at its source. Its lead candidate, LTG-001, is a potential best-in-class Nav1.8 inhibitor granted FDA Fast Track designation. Based in Thousand Oaks, California, Latigo has raised a $135M Series A and $150M Series B to advance its pipeline.

Summary

Latigo Biotherapeutics is a Biotech company based in Thousand Oaks, United States, founded in 2018. It has raised $285.0M in total across 2 rounds, most recently a $150.0M Series B round in Mar 2025. Investors include Blue Owl Capital, Westlake Village BioPartners and Deep Track Capital.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMar 2025
$150.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Latigo Biotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/latigo-biotherapeutics"><img src="https://indexed.vc/api/badge/company/latigo-biotherapeutics" alt="Latigo Biotherapeutics on Indexed.vc" width="260" height="76" /></a>